logo
Article

ISPAD 2024 Clinical Practice Consensus Guidelines

06 Aug, 2025
Diabetes

• Updated insulin treatment sections including new bolus and basal insulin formulations. 

• Updated recommendations on the principles of intensive insulin treatment regimens, including a more intensive form of multiple daily injections (MDIs) with new-generation faster-acting insulins and ultra-long-acting insulins, automated insulin delivery to achieve a high level of treatment personalization, better glycemia, and empowerment for people with diabetes. 

• Review of the roles and rationales for new insulin analogs, biosimilars, and diabetes technology devices for insulin therapy in pediatric diabetology 

• Summary of adjunctive medications used alongside insulin treatment that includes details on pramlintide, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA), and sodium-glucose cotransporter (SGLT) inhibitors. 

• Key considerations with regard to access to insulin and affordability specifically innovative, multi-faceted approaches involving governments, healthcare providers, pharmaceutical companies, and advocacy groups to ensure that all persons with diabetes who need insulin can obtain it without financial hardship 

 

lock

Exclusive for Healthcare professionals only

If you are a healthcare professional, please register/login to view the article
For Healthcare Professionals

Contact Us

eva logo

We empower the fight for health and well being as a human right.

Subscribe for our latest news and updates

For adverse events reporting, please contact us on

PV.Report@evapharma.com

© 2026 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية